Novartis's experimental cardiovascular drug pelacarsen failed to demonstrate a reduction in major cardiovascular events in a large Phase 3 trial, raising fresh questions about whether lowering an inherited cholesterol-related risk factor can prevent heart attacks and strokes.
The drug substantially reduced blood levels of lipoprotein(a), known as Lp(a), but the improvement did not translate into a statistically demonstrated cardiovascular benefit on the trial's primary endpoint. Novartis announced the setback on September 4, 2026.
Now, cardiologists are awaiting detailed findings from the Lp(a)HORIZON trial, scheduled for presentation at the American Heart Association's Scientific Sessions in Chicago on November 7. As Reuters reported on November 2, the results could help clarify whether the treatment produced a smaller-than-expected benefit, no measurable benefit, or outcomes that raise additional concerns.
What Happened in the Lp(a)HORIZON Trial?
The Phase 3 Lp(a)HORIZON trial enrolled 8,323 people with established cardiovascular disease and elevated Lp(a). Participants were randomly assigned to receive pelacarsen or a placebo while continuing guideline-directed cardiovascular care.
Pelacarsen, developed through a collaboration between Novartis and Ionis Pharmaceuticals, is an investigational antisense oligonucleotide designed to reduce the production of apolipoprotein(a), a key component of Lp(a). The treatment was administered as an 80-milligram injection approximately once a month.
The trial evaluated whether lowering Lp(a) could reduce a composite of four cardiovascular outcomes:
- Death from cardiovascular causes.
- Nonfatal heart attack.
- Nonfatal stroke.
- Urgent coronary revascularization requiring hospitalization, such as a procedure to restore blood flow to the heart.
According to Novartis's official announcement, the trial did not meet its primary endpoint compared with placebo, even though participants receiving pelacarsen achieved substantially lower Lp(a) levels.
Earlier clinical studies demonstrated Lp(a) reductions of approximately 80%. However, that figure describes a change in the biomarker, not an 80% reduction in heart attacks, strokes, or cardiovascular deaths.
The trial's registered design and outcome measures are available through ClinicalTrials.gov under NCT04023552.
Why Lowering Lp(a) May Not Be Enough
Lp(a) is a cholesterol-carrying particle whose concentration is largely determined by inherited genetics. Elevated levels have been associated with a greater risk of atherosclerotic cardiovascular disease and aortic valve disease. Unlike conventional LDL cholesterol, Lp(a) levels are generally not substantially changed by diet or exercise.
Approximately one in five people worldwide has elevated Lp(a), according to estimates cited by Novartis. Genetic research has also provided evidence supporting a causal role for Lp(a) in cardiovascular disease, making it an attractive target for drug development.
Yet a biological risk factor and a clinically effective treatment are not the same thing.
A drug can successfully change a laboratory measurement without necessarily preventing enough clinical events to demonstrate benefit in a randomized trial. That difference is central to interpreting the pelacarsen setback.
Several possible explanations require examination. The magnitude or duration of Lp(a) reduction may not have been sufficient to produce a detectable benefit during the study. The trial population, background treatment, or endpoint composition could also have affected the result. Alternatively, the treatment might not provide the expected clinical protection despite its effect on Lp(a).
These remain possibilities rather than established explanations. The topline announcement did not provide enough numerical detail to determine which interpretation is supported.
What Cardiologists Want to Learn From the Full Results
The November 7 presentation is expected to provide a more complete picture of the trial's cardiovascular outcomes, including analyses beyond the initial headline result.
One important question concerns the individual components of the primary endpoint. A composite outcome combines several types of events into a single measure, but the frequency and treatment effect for each component can differ.
Researchers will therefore examine whether pelacarsen showed any signal of benefit for heart attacks, strokes, cardiovascular deaths, or urgent revascularization procedures, even though the combined primary endpoint was not met.
Other important details include the absolute event rates in each treatment group, treatment-effect estimates and confidence intervals, follow-up duration, adverse events, and the number of participants who discontinued treatment.
The enrolled population also received established cardiovascular treatments, including medications to lower LDL cholesterol and manage blood pressure. Those therapies can reduce cardiovascular risk, making it important to evaluate what additional benefit, if any, pelacarsen provided.
The study included patients with Lp(a) concentrations of at least 70 mg/dL and a prespecified subgroup with concentrations of at least 90 mg/dL. Any differences between those populations will require careful statistical interpretation rather than conclusions based on isolated subgroup findings.
The American Heart Association's official program lists both the primary Lp(a)HORIZON findings and extended cardiovascular outcome analyses for Saturday, November 7, 2026.
What the Setback Means for Other Lp(a) Drugs
The failure of pelacarsen represents an important challenge for a wider field of experimental treatments designed to lower Lp(a).
Other pharmaceutical companies are developing approaches that target the same risk factor through different molecular technologies. These include Amgen's olpasiran and Eli Lilly's lepodisiran, both of which use small interfering RNA technology to suppress production of apolipoprotein(a).
Although these treatments have demonstrated substantial Lp(a) reductions in clinical research, reducing the biomarker is not itself proof that they prevent cardiovascular events.
The distinction matters because different drugs may vary in how strongly, how consistently, and for how long they reduce Lp(a). Their clinical trials may also involve different patient populations, follow-up periods, and outcome definitions.
As Reuters reported, major cardiovascular outcome results for competing Lp(a)-lowering treatments are expected later in the decade, including studies targeting readouts in 2028 and 2029.
Pelacarsen's disappointing result does not establish that those programs will fail. Equally, their promising biomarker reductions cannot be treated as evidence of proven cardiovascular protection until appropriately designed outcome trials demonstrate it.
What This Means for People With Elevated Lp(a)
The trial's outcome does not mean that elevated Lp(a) has become irrelevant to cardiovascular risk assessment.
The 2026 American Heart Association and American College of Cardiology dyslipidemia guideline supports measuring Lp(a) at least once during adulthood to help identify inherited cardiovascular risk.
Testing can provide useful information, particularly for people with a personal or family history of premature cardiovascular disease. A result should be interpreted alongside other established risk factors, rather than treated as an isolated prediction of an individual's likelihood of having a heart attack or stroke.
For people with elevated Lp(a), established cardiovascular prevention remains important. Depending on an individual's clinical circumstances, this may include managing LDL cholesterol, blood pressure, diabetes, smoking exposure, and other modifiable risk factors.
Lifestyle changes generally do not substantially lower genetically determined Lp(a) concentrations, but they can still improve overall cardiovascular health.
Pelacarsen remains investigational and is not an approved treatment for reducing cardiovascular events. Its trial failure does not justify stopping prescribed cholesterol-lowering medications or other established cardiovascular treatments.
The central unanswered question is whether selectively lowering Lp(a) can produce a meaningful improvement in clinical outcomes beyond existing treatment. The detailed Lp(a)HORIZON findings scheduled for November 7 should provide more evidence about pelacarsen's results, but determining the broader future of Lp(a)-targeted treatment will require careful analysis and additional clinical research.
 Treatments){kind=link}
0 Comments